Revelation Net Debt To E B I T D A from 2010 to 2024
| REVB Stock | USD 0.76 0.01 0.67% |
Net Debt To EBITDA | First Reported 2010-12-31 | Previous Quarter 125.95266154 | Current Value 132.25 | Quarterly Volatility 37.76455714 |
Check Revelation Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Revelation Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 42.2 K, Total Revenue of 0.0 or Other Operating Expenses of 5.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.54. Revelation financial statements analysis is a perfect complement when working with Revelation Biosciences Valuation or Volatility modules.
Revelation | Net Debt To E B I T D A |
Latest Revelation Biosciences' Net Debt To E B I T D A Growth Pattern
Below is the plot of the Net Debt To E B I T D A of Revelation Biosciences over the last few years. It is a leverage ratio that indicates a company's ability to pay off its incurred debt. It compares a company's net debt (total debt minus cash) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). Revelation Biosciences' Net Debt To EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Revelation Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Net Debt To E B I T D A | 10 Years Trend |
|
Net Debt To E B I T D A |
| Timeline |
Revelation Net Debt To E B I T D A Regression Statistics
| Arithmetic Mean | 39.90 | |
| Geometric Mean | 19.40 | |
| Coefficient Of Variation | 94.66 | |
| Mean Deviation | 23.79 | |
| Median | 30.88 | |
| Standard Deviation | 37.76 | |
| Sample Variance | 1,426 | |
| Range | 132 | |
| R-Value | 0.43 | |
| Mean Square Error | 1,258 | |
| R-Squared | 0.18 | |
| Significance | 0.11 | |
| Slope | 3.59 | |
| Total Sum of Squares | 19,966 |
Revelation Net Debt To E B I T D A History
About Revelation Biosciences Financial Statements
Revelation Biosciences stakeholders use historical fundamental indicators, such as Revelation Biosciences' Net Debt To E B I T D A, to determine how well the company is positioned to perform in the future. Although Revelation Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Revelation Biosciences' assets and liabilities are reflected in the revenues and expenses on Revelation Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Revelation Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Debt To EBITDA | 125.95 | 132.25 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Revelation Biosciences is a strong investment it is important to analyze Revelation Biosciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Revelation Biosciences' future performance. For an informed investment choice regarding Revelation Stock, refer to the following important reports:Check out the analysis of Revelation Biosciences Correlation against competitors. For information on how to trade Revelation Stock refer to our How to Trade Revelation Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Revelation Biosciences. If investors know Revelation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Revelation Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (17.53) | Return On Assets (0.51) | Return On Equity (2.70) |
The market value of Revelation Biosciences is measured differently than its book value, which is the value of Revelation that is recorded on the company's balance sheet. Investors also form their own opinion of Revelation Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Revelation Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Revelation Biosciences' market value can be influenced by many factors that don't directly affect Revelation Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Revelation Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Revelation Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Revelation Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.